MAPT and Alzheimer disease: Application of synthetic and AD patient-derived Aβ oligomers (oAβs) can cause tau hyperphosphorylation and synaptic damage in cultured neurons, which can be inhibited by tau reduction or by blocking tau phosphorylation16, 17, 18.